In this expert perspective, Manjot K. Gill, MD, discusses faricimab for the management of retinal vein occlusion.

If approved, Eylea would be the first treatment for RVO with 8-week dosing. The FDA target action date is Aug. 19, 2025.

traction retinal detachment and angle closure. Diabetes has widespread effects on the vascular system, which can lead to retinal vein and artery occlusions, ocular ischemic syndrome and non ...

In this expert perspective, Manjot K. Gill, MD, discusses the potential FDA approval in 2025 of aflibercept 8 mg for the treatment of retinal vein occlusion.

Six of 7 eyes with incarcerations posterior to the vortex vein ampullae ... of conventional retinal detachment surgery: identify all retinal breaks, release traction, and reattach the retina.

EYLEA HD is a treatment for retinal vein occlusion (RVO) that allows for dosing every 8 weeks after initial monthly doses, potentially halving injections. What is the FDA's action date for EYLEA ...